Continuing Adjuvant Temozolomide Beyond Six Cycles in GBM Does Not Improve PFS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)
Neuro-oncology 2020 Apr 24;[EPub Ahead of Print], C Balana, MA Vaz, JM Sepúlveda, C Mesia, S Del Barco, E Pineda, J Muñoz-Langa, A Estival, R de Las Peñas, J Fuster, R Gironés, LM Navarro, M Gil-Gil, M Alonso, A Herrero, S Peralta, C Olier, P Perez-Segura, M Covela, M Martinez-García, A Berrocal, O Gallego, R Luque, FJ Perez-Martín, A Esteve, N Munne, M Domenech, S Villa, C Sanz, C CarratoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.